Abstract
Cystic Fibrosis (CF) is a chronic, multi-system disorder that primarily affects the lungs, and pancreas, and leads to significant and progressive bronchiectasis, and subsequently end-stage lung disease. Sleep disturbances in cystic fibrosis include nocturnal hypoxemia due to a variety of physiologic changes including ventilation-perfusion mismatch, changes in mechanics of breathing. Derecruitment of ventilatory muscles, particularly during REM sleep and resultant hypoventilation may also be contributory, and may also lead to sleep-disordered breathing in these patients. Other potential causes of sleep disruption in CF patients include nocturnal wheezing and cough, as well as side effects of medications such as β-agonists, as well as chronic pain syndromes. It is likely that sleep fragmentation contributes significantly to impaired quality of life in CF patients. Nocturnal ventilation has been shown to improve symptoms, reverse hypoventilation and increase exercise capacity in CF patients.
Keywords: Sleep, cystic fibrosis, bronchospasm, nocturnal respiratory failure
Current Respiratory Medicine Reviews
Title: Sleep Disturbances in Cystic Fibrosis
Volume: 5 Issue: 4
Author(s): Amarbir S. Mattewal and Shyamsunder Subramanian
Affiliation:
Keywords: Sleep, cystic fibrosis, bronchospasm, nocturnal respiratory failure
Abstract: Cystic Fibrosis (CF) is a chronic, multi-system disorder that primarily affects the lungs, and pancreas, and leads to significant and progressive bronchiectasis, and subsequently end-stage lung disease. Sleep disturbances in cystic fibrosis include nocturnal hypoxemia due to a variety of physiologic changes including ventilation-perfusion mismatch, changes in mechanics of breathing. Derecruitment of ventilatory muscles, particularly during REM sleep and resultant hypoventilation may also be contributory, and may also lead to sleep-disordered breathing in these patients. Other potential causes of sleep disruption in CF patients include nocturnal wheezing and cough, as well as side effects of medications such as β-agonists, as well as chronic pain syndromes. It is likely that sleep fragmentation contributes significantly to impaired quality of life in CF patients. Nocturnal ventilation has been shown to improve symptoms, reverse hypoventilation and increase exercise capacity in CF patients.
Export Options
About this article
Cite this article as:
Mattewal S. Amarbir and Subramanian Shyamsunder, Sleep Disturbances in Cystic Fibrosis, Current Respiratory Medicine Reviews 2009; 5 (4) . https://dx.doi.org/10.2174/157339809790112401
DOI https://dx.doi.org/10.2174/157339809790112401 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets Environmental Factors and Hypertension
Current Pharmaceutical Design Going Beyond Anthracyclines and Taxanes in Breast Cancer – What’s Next?
Current Cancer Therapy Reviews Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Fish Oil Fatty Acids as Cardiovascular Drugs
Current Vascular Pharmacology A Bioinorganic Perspective on Matrix Metalloproteinase Inhibition
Current Topics in Medicinal Chemistry Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design Sirtuin3 in Neurological Disorders
Current Drug Research Reviews Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews Proteomic Analysis of Mitochondrial Proteins on the Mechanism of Apoptotic Under Amorphophallus konjac Tuber (KONJAC) Extracts in Gas tric Cancer Cell
Current Proteomics Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development
Recent Patents on Anti-Cancer Drug Discovery General or Local Anesthesia for TAVI? A Systematic Review of the Literature and Meta-Analysis
Current Pharmaceutical Design A Pharmacological Primer of Biased Agonism
Endocrine, Metabolic & Immune Disorders - Drug Targets Heart Failure in North America
Current Cardiology Reviews Key Role of Mitochondria in Alzheimer’s Disease Synaptic Dysfunction
Current Pharmaceutical Design Renoprotection with Anti-Hypertensives: Reduction of Proteinuria and Improvement of Oxygenation via Inhibition of the Renin-Angiotensin System
Current Hypertension Reviews Could Additional Inhibitors of the Renin -Angiotensin System be Clinically Useful?
Current Hypertension Reviews P2X Receptors in the Cardiovascular System and their Potential as Therapeutic Targets in Disease
Current Medicinal Chemistry